World's Best Scientists 2026 revealed!
Laurence Albiges

Laurence Albiges

D-Index & Metrics

Medicine

D-Index
83
Citations
38765
World Ranking
15374
National Ranking
496

Laurence Albiges publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Laurence Albiges sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 606 publications — 72nd percentile

72% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Laurence Albiges D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Laurence Albiges sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 83 D-Index — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Laurence Albiges is affiliated with the Institut Gustave Roussy in France and has contributed extensively to medical research, particularly in the field of oncology and renal cell carcinoma treatment. Their work spans multiple areas including cancer immunotherapy, molecular biology, and cancer genomics, reflecting a multidisciplinary approach to cancer research.

Their main fields of study include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

More specifically, the subfields they have worked in are:

  • Pulmonary and Respiratory Medicine
  • Oncology
  • Molecular Biology
  • Cancer Research
  • Economics and Econometrics

The primary topics Laurence Albiges focuses on include:

  • Renal cell carcinoma treatment
  • Cancer Immunotherapy and Biomarkers
  • Renal and related cancers
  • Cancer Genomics and Diagnostics
  • Economic and Financial Impacts of Cancer
  • Bladder and Urothelial Cancer Treatments
  • Pancreatic and Hepatic Oncology Research

Laurence Albiges has co-authored with leading experts in the field, frequently collaborating with:

  • Toni K. Choueiri
  • Bernard Escudier
  • Gwénaëlle Gravis
  • Ronan Flippot
  • Brian I. Rini

The researcher publishes regularly in several prominent venues, including:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • European Urology
  • European Journal of Cancer
  • European Urology Oncology

Significant recent publications by Laurence Albiges include:

  • "Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial," 2020, ESMO Open
  • "European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update," 2022, European Urology

Other relevant notable papers in their field, although authored by collaborators, which are closely related to their research interests, include:

  • "Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial," 2020, Nature Medicine
  • "Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma," 2020, Annals of Oncology
  • "Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage," 2020, Science

Best Publications

  • Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

    Bertrand Routy;Bertrand Routy;Bertrand Routy;Lisa Derosa;Lisa Derosa;Lisa Derosa;Connie P. M. Duong;Connie P. M. Duong

  • Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

    Robert J. Motzer;Konstantin Penkov;John Haanen;Brian Rini

  • Renal cell carcinoma.

    James J. Hsieh;Mark P. Purdue;Sabina Signoretti;Charles Swanton

  • Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.

    W. Marston Linehan;Paul T. Spellman;Christopher J. Ricketts;Chad J. Creighton

  • Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.

    Arnaud Méjean;Alain Ravaud;Simon Thezenas;Sandra Colas

  • Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer

    L. Derosa;L. Derosa;L. Derosa;M.D. Hellmann;M.D. Hellmann;M. Spaziano;D. Halpenny

  • Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.

    Gwenaelle Gravis;Jean-Marie Boher;Florence Joly;Michel Soulié

  • Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data

    Claire L. Vale;Sarah Burdett;Larysa H. M. Rydzewska;Laurence Albiges

  • Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.

    Laurence Albiges;Nizar M. Tannir;Mauricio Burotto;David McDermott;David McDermott

  • Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)

    Y. Loriot;D. Bianchini;E. Ileana;S. Sandhu

  • Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial.

    Robert J. Motzer;Paul B. Robbins;Thomas Powles;Laurence Albiges

  • Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.

    T.K. Choueiri;R.J. Motzer;B.I. Rini;J. Haanen

  • Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report.

    Jean-Marie Michot;Laurence Albiges;Nathalie Chaput;Veronique Saada

  • Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage.

    Aurélie Fluckiger;Aurélie Fluckiger;Romain Daillère;Romain Daillère;Mohamed Sassi;Barbara Susanne Sixt

  • Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non–Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial

    Nizar M. Tannir;Eric Jonasch;Laurence Albiges;Emre Altinmakas

  • PD-L1 expression in nonclear-cell renal cell carcinoma

    T. K. Choueiri;T. K. Choueiri;A. P. Fay;K. P. Gray;M. Callea

  • Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.

    François-Xavier Danlos;Anne-Laure Voisin;Valérie Dyevre;Jean-Marie Michot

  • Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.

    Toni K. Choueiri;Mayer Fishman;Bernard Escudier;David F. McDermott

  • Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus.

    G. Curigliano;S. Banerjee;A. Cervantes;A. Cervantes;M.C. Garassino

  • Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma

    Marcella Callea;Laurence Albiges;Mamta Gupta;Mamta Gupta;Su-Chun Cheng

Frequent Co-Authors

Bernard Escudier
Bernard Escudier Institut Gustave Roussy
Toni K. Choueiri
Toni K. Choueiri Harvard University
Karim Fizazi
Karim Fizazi University of Paris-Saclay
Yohann Loriot
Yohann Loriot University of Paris-Saclay
Thomas Powles
Thomas Powles Queen Mary University of London
Robert J. Motzer
Robert J. Motzer Memorial Sloan Kettering Cancer Center
Stéphane Oudard
Stéphane Oudard Hôpital Européen Georges-Pompidou
Brian I. Rini
Brian I. Rini Vanderbilt University Medical Center
Christine Chevreau
Christine Chevreau DuPont (United States)
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students exploring Medicine in the USA, there are a growing number of online degree options that can lead to rewarding healthcare careers. Online programs offer flexibility for working adults and those seeking to advance their education while balancing other commitments.

If you’re interested in healthcare leadership, consider enrolling in cheap mha programs to prepare for management positions. For nurses aiming to reach advanced practice or leadership roles, some of the cheapest bsn to dnp programs offer a direct, affordable pathway from a BSN to a Doctor of Nursing Practice degree.

Aspiring pharmacists now have more options as well. Many online pharmacy schools provide flexible, accredited doctorate programs that can be pursued from anywhere in the country. Meanwhile, those interested in the intersection of technology, data, and healthcare may want to explore online schools for health information management—a field that’s rapidly growing alongside electronic medical record adoption.

With these online healthcare degrees, students can access new career pathways in the medical field and make valuable contributions to the future of healthcare in the USA.

Best Scientists Citing Laurence Albiges

Trending Scientists

Recently Published Articles